155 related articles for article (PubMed ID: 19222740)
1. Should dialysate calcium concentration be standardised or individualised?
Lindley EJ
J Ren Care; 2009 Mar; 35 Suppl 1():101-6. PubMed ID: 19222740
[TBL] [Abstract][Full Text] [Related]
2. Calcium balance in dialysis is best managed by adjusting dialysate calcium guided by kinetic modeling of the interrelationship between calcium intake, dose of vitamin D analogues and the dialysate calcium concentration.
Gotch F; Levin NW; Kotanko P
Blood Purif; 2010; 29(2):163-76. PubMed ID: 20093823
[TBL] [Abstract][Full Text] [Related]
3. Review of dialysate calcium concentration in hemodialysis.
Toussaint N; Cooney P; Kerr PG
Hemodial Int; 2006 Oct; 10(4):326-37. PubMed ID: 17014507
[TBL] [Abstract][Full Text] [Related]
4. Effect of treatment with 1.25 and 1.75 mmol/l calcium dialysate on bone mineral density in haemodialysis patients.
Van der Niepen P; Sennesael J; Louis O; Verbeelen D
Nephrol Dial Transplant; 1995 Dec; 10(12):2253-8. PubMed ID: 8808221
[TBL] [Abstract][Full Text] [Related]
5. Consequences of the implementation of K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease in a population of patients on chronic hemodialysis.
Arenas MD; Alvarez-Ude F; Torregrosa V; Gil MT; Carretón MA; Moledous A; Nuñez C; Devesa R; Albiach B
J Nephrol; 2007; 20(4):453-61. PubMed ID: 17879212
[TBL] [Abstract][Full Text] [Related]
6. Reversal of adynamic bone disease by lowering of dialysate calcium.
Haris A; Sherrard DJ; Hercz G
Kidney Int; 2006 Sep; 70(5):931-7. PubMed ID: 16837920
[TBL] [Abstract][Full Text] [Related]
7. Application of NKF-K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease: changes of clinical practices and their effects on outcomes and quality standards in three haemodialysis units.
Arenas MD; Alvarez-Ude F; Gil MT; Soriano A; Egea JJ; Millán I; Amoedo ML; Muray S; Carretón MA
Nephrol Dial Transplant; 2006 Jun; 21(6):1663-8. PubMed ID: 16464885
[TBL] [Abstract][Full Text] [Related]
8. Calcium mass balances during standard bicarbonate hemodialysis and long-hour slow-flow bicarbonate hemodialysis.
Basile C; Libutti P; Di Turo AL; Tundo S; Maselli P; Casucci F; Losurdo N; Teutonico A; Vernaglione L; Lomonte C
J Nephrol; 2011; 24(6):742-8. PubMed ID: 21360470
[TBL] [Abstract][Full Text] [Related]
9. Low calcium (1.25 mmol/L) dialysate can normalize relative hypoparathyroidism in CAPD patients with low bone turnover.
Shigematsu T; Kawaguchi Y; Kubo H; Nakayama M; Kato N; Yamamoto H; Osaka N; Hayakawa H; Ogawa A; Sakai O
Adv Perit Dial; 1996; 12():250-6. PubMed ID: 8865914
[TBL] [Abstract][Full Text] [Related]
10. Nocturnal but not short hours quotidian hemodialysis requires an elevated dialysate calcium concentration.
Al-Hejaili F; Kortas C; Leitch R; Heidenheim AP; Clement L; Nesrallah G; Lindsay RM
J Am Soc Nephrol; 2003 Sep; 14(9):2322-8. PubMed ID: 12937309
[TBL] [Abstract][Full Text] [Related]
11. Calcium kinetics and the long-term effects of lowering dialysate calcium concentration.
Argilés A; Kerr PG; Canaud B; Flavier JL; Mion C
Kidney Int; 1993 Mar; 43(3):630-40. PubMed ID: 8455362
[TBL] [Abstract][Full Text] [Related]
12. Calcium exposure and removal in chronic hemodialysis patients.
Sigrist M; McIntyre CW
J Ren Nutr; 2006 Jan; 16(1):41-6. PubMed ID: 16414440
[TBL] [Abstract][Full Text] [Related]
13. Calcium balance in haemodialysis--do not lower the dialysate calcium concentration too much (con part).
Drüeke TB; Touam M
Nephrol Dial Transplant; 2009 Oct; 24(10):2990-3. PubMed ID: 19666667
[TBL] [Abstract][Full Text] [Related]
14. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
15. High-normal calcium (1.35 mmol/l) dialysate in patients on CAPD: efficient and safe long-term control of plasma calcium, phosphate, and parathyroid hormone.
Bro S; Brandi L; Olgaard K
Nephrol Dial Transplant; 1996 Aug; 11(8):1586-91. PubMed ID: 8856216
[TBL] [Abstract][Full Text] [Related]
16. Achieving K/DOQI laboratory target values for bone and mineral metabolism: an uphill battle.
Al Aly Z; González EA; Martin KJ; Gellens ME
Am J Nephrol; 2004; 24(4):422-6. PubMed ID: 15308874
[TBL] [Abstract][Full Text] [Related]
17. Mineral and bone disorders in patients on dialysis: physiology and clinical consequences.
McCarley PB; Arjomand M
Nephrol Nurs J; 2008; 35(1):59-64. PubMed ID: 18372764
[TBL] [Abstract][Full Text] [Related]
18. Different routes bridging calcium in Japanese hemodialysis patients.
Hamano T; Fujii N; Ito T; Imai E
Ther Apher Dial; 2005 Feb; 9(1):32-8. PubMed ID: 15828903
[TBL] [Abstract][Full Text] [Related]
19. Reappraisal of 2003 NKF-K/DOQI guidelines for management of hyperparathyroidism in chronic kidney disease patients.
Monge M; Shahapuni I; Oprisiu R; El Esper N; Morinière P; Massy Z; Choukroun G; Fournier A
Nat Clin Pract Nephrol; 2006 Jun; 2(6):326-36. PubMed ID: 16932454
[TBL] [Abstract][Full Text] [Related]
20. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
